. Author manuscript; available in PMC: 2009 Jul 21.

Published in final edited form as: Pharmacogenet Genomics. 2007 Sep;17(9):719–729. doi: 10.1097/FPC.0b013e32810f2e3c

Table 3.

KCNMB1 genotype frequency by race/ethnicity and in INVEST-GENES

	INVEST-GENES	Verapamil monotherapy	Stable background therapy	White	Hispanic	Black	Other
Glu65Glu	1412 (77%)	121 (75%)	454 (75%)	743 (81%)	466 (73%)	153 (76%)	50 (79%)
Glu65Lys	392 (22%)	40 (24%)	143 (24%)	165 (18%)	169 (26%)	45 (23%)	13 (21%)
Lys65Lys	20 (1%)	2 (1%)	4 (1%)	9 (1%)	9 (1%)	2 (1%)	0
Lys65 allele frequency	0.12	0.135	0.13	0.10	0.14	0.13	0.10
Val110Val	4591 (84%)	128 (79%)	493 (82%)	1782 (86%)	2143 (83%)	480 (82%)	186 (83%)
Val110Leu	843 (15%)	32 (20%)	103 (17%)	273 (13%)	432 (17%)	103 (18%)	35 (16%)
Leu110Leu	52 (1%)	2 (1%)	2 ( < 1%)	21 (1%)	23 (1%)	5 (1%)	3 (1%)
Leu110 allele frequency	0.09	0.105	0.09	0.08	0.09	0.10	0.09